Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Liver Cancer Diagnostics Market?

In recent times, there has been substantial growth in the liver cancer diagnostics market. It is projected to rise from $9.69 billion in 2024 to $10.4 billion in 2025, recording a compound annual growth rate (CAGR) of 7.3%. The earlier growth experienced can be traced back to advancements in biopsy processes and histopathology, the emergence of biomarker detection, the adaptation of screening programs, developments in genetic tests, and enhancement in liver imaging modalities.

What Growth Rate Is Forecasted for the Liver Cancer Diagnostics Market by 2029?

In the coming years, the liver cancer diagnostics market size is projected to experience significant growth, reaching “$13.86 billion in 2029 with a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period can be credited to the regulatory and standardization changes, the rising significance of imaging modalities, the advent of next-generation sequencing, the extension of screening programs and awareness, and an increasing demand for biomarker-based tests. The forecast period will also witness major trends such as an increased incidence and prevalence, advancements in imaging technologies, emphasis on non-invasive diagnostics, precision medicine and personalized diagnostics, as well as the integration of artificial intelligence (AI).

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

Which Key Companies Are Shaping the Future of the Liver Cancer Diagnostics Market?

Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

Which Factors Are Driving Demand in the Liver Cancer Diagnostics Industry?

The increasing occurrence of liver carcinoma is anticipated to drive the liver cancer diagnostics market’s expansion. Liver cancer is characterized by uncontrolled multiplication and growth of liver cells, resulting in a fatal disease. Diagnostic tests for liver cancer are used to identify the spread of cancer cells within or around the liver, following the initial diagnosis of liver carcinoma. This increase in liver cancer occurrences bolsters the growth of the liver cancer diagnostics market. For example, the American Cancer Society, a US-based nonprofit health association, reported in their Cancer Facts & Figures 2023 report that the number of new female cases of liver and intrahepatic bile duct cancer rose to 13,230 in 2023, up from 12,640 in 2020, in the United States. Additionally, it is projected that the US will diagnose 41,210 new cases of liver cancer in 2023, and approximately 29,380 individuals are expected to pass away from it. Therefore, the escalating occurrence of liver cancer fuels the expansion of the liver cancer diagnostic market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10481&type=smp

How Is the Liver Cancer Diagnostics Market Segmented by Several Divisions?

The liver cancer diagnostics market covered in this report is segmented –

1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types

2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings

3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories

Subsegments:

1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma

2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma

3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma

4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma

What are the Emerging Market Trends Driving the Growth of the Liver Cancer Diagnostics Industry?

Leading firms in the liver cancer diagnostics market are introducing innovative biomarker-based tests and decision-making processes with the aim to enhance diagnostic accuracy and encourage early detection. Biomarker-based tests and decision-making processes are diagnostic tools that use specific biological signs to detect diseases, offering more accurate and effective diagnostic abilities. For example, Roche Diagnostics, a biotech company based in the US, introduced the Elecsys PIVKA-II test and the Elecsys GAAD decision-making process in November 2023. The Elecsys PIVKA-II test uncovers increased levels of the PIVKA-II biomarker, which is linked with hepatocellular carcinoma (HCC), reinforcing early detection of liver cancer in patients at high risk. The Elecsys GAAD decision-making process merges multiple diagnostic indicators, such as PIVKA-II and AFP, to boost diagnostic accuracy and simplify decision-making in detecting liver cancer.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Which Regions Are Driving Growth in the Liver Cancer Diagnostics Market?

North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10481

This Report Delivers Insight On:

1. How big is the liver cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the liver cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the liver cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the liver cancer diagnostics market?

5. What factors are helping or slowing down the growth of the liver cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model